Table of Contents Author Guidelines Submit a Manuscript
Obstetrics and Gynecology International
Volume 2011, Article ID 358493, 9 pages
http://dx.doi.org/10.1155/2011/358493
Review Article

Ovarian Epithelial-Stromal Interactions: Role of Interleukins 1 and 6

1Department of Pathology & Cell Biology, MDC 11, University of South Florida, 12901 Bruce B. Downs Blvd., Tampa, FL 33612, USA
2H. Lee Moffitt Cancer Center, Tampa, FL 33612, USA

Received 1 February 2011; Revised 12 April 2011; Accepted 27 April 2011

Academic Editor: Eddie Murta

Copyright © 2011 Kamisha T. Woolery and Patricia A. Kruk. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. W. J. Hoskins, “Prospective on ovarian cancer: why prevent?” Journal of Cellular Biochemistry, vol. 59, no. 23, supplement, pp. 189–199, 1995. View at Publisher · View at Google Scholar · View at Scopus
  2. R. F. Ozols, “Ovarian cancer, Part II: treatment,” Current Problems in Cancer, vol. 16, no. 2, pp. 67–126, 1992. View at Google Scholar · View at Scopus
  3. R. E. Scully, “Pathology of ovarian cancer precursors,” Journal of Cellular Biochemistry, vol. 59, no. 23, pp. 208–218, 1995. View at Publisher · View at Google Scholar · View at Scopus
  4. R. T. Greenlee, T. Murray, S. Bolden, and P. A. Wingo, “Cancer statistics, 2000,” Ca-A Cancer Journal for Clinicians, vol. 50, no. 1, pp. 7–33, 2000. View at Google Scholar · View at Scopus
  5. E. C. Kohn, G. Sarosy, A. Bicher et al., “Dose-intense taxol: high response rate in patients with platinum-resistant recurrent ovarian cancer,” Journal of the National Cancer Institute, vol. 86, no. 1, pp. 18–24, 1994. View at Google Scholar · View at Scopus
  6. G. Blackledge, F. Lawton, C. Redman, and K. Kelly, “Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and the design of phase II trials,” British Journal of Cancer, vol. 59, no. 4, pp. 650–653, 1989. View at Google Scholar · View at Scopus
  7. J. T. Thigpen, J. A. Blessing, H. Ball, S. J. Hummel, and R. J. Barrett, “Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study,” Journal of Clinical Oncology, vol. 12, no. 9, pp. 1748–1753, 1994. View at Google Scholar · View at Scopus
  8. G. J. Creemers, G. Bolis, M. Gore et al., “Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study,” Journal of Clinical Oncology, vol. 14, no. 12, pp. 3056–3061, 1996. View at Google Scholar · View at Scopus
  9. A. Gordon, J. Carmichael, and J. Malfetano, “Final analysis of a phase III randomized study of topotecan vs. paclitaxel in advanced epithelial ovarian cancer,” International Topotecan Study Group, vol. 17, article 356a, 1997. View at Google Scholar
  10. M. Kaufmann and G. von Minckwitz, “Gemcitabine in ovarian cancer: an overview of safety and efficacy,” European Journal of Cancer Part A, vol. 33, no. 1, supplement, pp. S31–S33, 1997. View at Google Scholar · View at Scopus
  11. F. M. Muggia, J. D. Hainsworth, S. Jeffers et al., “Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation,” Journal of Clinical Oncology, vol. 15, no. 3, pp. 987–993, 1997. View at Google Scholar · View at Scopus
  12. R. F. Ozols, “Treatment of recurrent ovarian cancer: increasing options - 'Recurrent' results,” Journal of Clinical Oncology, vol. 15, no. 6, pp. 2177–2180, 1997. View at Google Scholar · View at Scopus
  13. W. T. B. Huinink, M. Gore, J. Carmichael et al., “Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer,” Journal of Clinical Oncology, vol. 15, no. 6, pp. 2183–2193, 1997. View at Google Scholar · View at Scopus
  14. M. A. Bookman, H. Malmström, G. Bolis et al., “Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel,” Journal of Clinical Oncology, vol. 16, no. 10, pp. 3345–3352, 1998. View at Google Scholar · View at Scopus
  15. P. G. Rose, J. A. Blessing, A. R. Mayer, and H. D. Homesley, “Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a gynecologic oncology group study,” Journal of Clinical Oncology, vol. 16, no. 2, pp. 405–410, 1998. View at Google Scholar · View at Scopus
  16. C. Percy and C. Muir, “The international comparability of cancer mortality data. Results of an international death certificate study,” American Journal of Epidemiology, vol. 129, no. 5, pp. 934–946, 1989. View at Google Scholar · View at Scopus
  17. H. T. Lynch, P. Watson, J. F. Lynch, T. A. Conway, and M. Fili, “Hereditary ovarian cancer: heterogeneity in age at onset,” Cancer, vol. 71, no. 2, supplement, pp. 573–581, 1993. View at Google Scholar · View at Scopus
  18. B. L. Harlow and N. S. Weiss, “Familial ovarian cancer: a population-based case-control study,” American Journal of Epidemiology, vol. 130, no. 5, pp. 1071–1072, 1989. View at Google Scholar · View at Scopus
  19. E. Negri, S. Franceschi, A. Tzonou et al., “Pooled analysis of 3 European case-control studies: I. Reproductive factors and risk of epithelial ovarian cancer,” International Journal of Cancer, vol. 49, no. 1, pp. 50–56, 1991. View at Google Scholar · View at Scopus
  20. L. Villard-Mackintosh, M. P. Vessey, and L. Jones, “The effects of oral contraceptives and parity on ovarian cancer trends in women under 55 years of age,” British Journal of Obstetrics and Gynaecology, vol. 96, no. 7, pp. 783–788, 1989. View at Google Scholar · View at Scopus
  21. A. P. Schneider II, “Risk factor for ovarian cancer,” The New England Journal of Medicine, vol. 317, no. 8, pp. 508–509, 1987. View at Google Scholar · View at Scopus
  22. J. T. Casagrande, E. W. Louie, and M. C. Pike, “'Incessant ovulation' and ovarian cancer,” The Lancet, vol. 2, no. 8135, pp. 170–173, 1979. View at Google Scholar · View at Scopus
  23. H. Kuper, L. Titus-Ernstoff, B. L. Harlow, and D. W. Cramer, “Population based study of coffee, alcohol and tobacco use and risk of ovarian cancer,” International Journal of Cancer, vol. 88, no. 2, pp. 313–318, 2000. View at Google Scholar · View at Scopus
  24. K. M. Fairfield, S. E. Hankinson, B. A. Rosner, D. J. Hunter, G. A. Colditz, and W. C. Willett, “Risk of ovarian carcinoma and consumption of vitamins A, C, and E and specific carotenoids: a prospective analysis,” Cancer, vol. 92, no. 9, pp. 2318–2326, 2001. View at Google Scholar · View at Scopus
  25. S. H. Olson, L. Mignone, C. Nakraseive, T. A. Caputo, R. R. Barakat, and S. Harlap, “Symptoms of ovarian cancer,” Obstetrics and Gynecology, vol. 98, no. 2, pp. 212–217, 2001. View at Publisher · View at Google Scholar · View at Scopus
  26. N. Einhorn, K. Sjovall, R. C. Knapp et al., “Prospective evaluation of serum CA 125 levels for early detection of ovarian cancer,” Obstetrics and Gynecology, vol. 80, no. 1, pp. 14–18, 1992. View at Google Scholar · View at Scopus
  27. Y. Carmi, E. Voronov, S. Dotan et al., “The role of macrophage-derived IL-1 in induction and maintenance of angiogenesis,” Journal of Immunology, vol. 183, no. 7, pp. 4705–4714, 2009. View at Publisher · View at Google Scholar · View at PubMed
  28. R. N. Apte, Y. Krelin, X. Song et al., “Effects of micro-environment- and malignant cell-derived interleukin-1 in carcinogenesis, tumour invasiveness and tumour-host interactions,” European Journal of Cancer, vol. 42, no. 6, pp. 751–759, 2006. View at Publisher · View at Google Scholar · View at PubMed
  29. X. Song, E. Voronov, T. Dvorkin et al., “Differential effects of IL-1α and IL-1β on tumorigenicity patterns and invasiveness,” Journal of Immunology, vol. 171, no. 12, pp. 6448–6456, 2003. View at Google Scholar
  30. E. Voronov, Y. Weinstein, D. Benharroch et al., “Antitumor and immunotherapeutic effects of activated invasive T lymphoma cells that display short-term interleukin 1α expression,” Cancer Research, vol. 59, no. 5, pp. 1029–1035, 1999. View at Google Scholar
  31. C. A. Dinarello, “Why not treat human cancer with interleukin-1 blockade?” Cancer and Metastasis Reviews, vol. 29, no. 2, pp. 317–329, 2010. View at Publisher · View at Google Scholar · View at PubMed
  32. M. Zoller, A. Douvdevani, S. Segal, and R. N. Apte, “Interleukin-1 produced by tumorigenic fibroblasts influences tumor rejection,” International Journal of Cancer, vol. 50, no. 3, pp. 443–449, 1992. View at Google Scholar
  33. M. Zoller, A. Douvdevani, S. Segal, and R. N. Apte, “Interleukin-1 production by transformed fibroblasts. II. Influence on antigen presentation and T-cell-mediated anti-tumor response,” International Journal of Cancer, vol. 50, no. 3, pp. 450–457, 1992. View at Google Scholar
  34. S. Vadhan-Raj, A. P. Kudelka, L. Garrison et al., “Effects of interleukin-1α on carboplatin-induced thrombocytopenia in patients with recurrent ovarian cancer,” Journal of Clinical Oncology, vol. 12, no. 4, pp. 707–714, 1994. View at Google Scholar
  35. J. W. Smith, W. J. Urba, B. D. Curti et al., “The toxic and hematologic effects of interleukin-1 alpha administered in a phase I trial to patients with advanced malignancies,” Journal of Clinical Oncology, vol. 10, no. 7, pp. 1141–1152, 1992. View at Google Scholar
  36. C. Denkert, I. Koch, S. Berger, M. Köbel, A. Siegert, and S. Hauptmann, “Cytokine-suppressive anti-inflammatory drugs (CSAIDs) inhibit invasion and MMP-1 production of ovarian carcinoma cells,” Cancer Letters, vol. 195, no. 1, pp. 101–109, 2003. View at Publisher · View at Google Scholar
  37. S. Stadlmann, A. Amberger, J. Pollheimer et al., “Ovarian carcinoma cells and IL-1β-activated human peritoneal mesothelial cells are possible sources of vascular endothelial growth factor in inflammatory and malignant peritoneal effusions,” Gynecologic Oncology, vol. 97, no. 3, pp. 784–789, 2005. View at Publisher · View at Google Scholar · View at PubMed
  38. H. Chen, W. W. Yang, Q. T. Wen, LI. Xu, and M. Chen, “TGF-β-induced fibroblast activation protein expression, fibroblast activation protein expression increases the proliferation, adhesion, and migration of HO-8910PM,” Experimental and Molecular Pathology, vol. 87, no. 3, pp. 189–194, 2009. View at Publisher · View at Google Scholar · View at PubMed
  39. C. A. Dinarello, “Immunological and inflammatory functions of the interleukin-1 family,” Annual Review of Immunology, vol. 27, pp. 519–550, 2009. View at Publisher · View at Google Scholar · View at PubMed
  40. A. Mustea, C. Pirvulescu, D. Könsgen et al., “Decreased IL-1 RA concentration in ascites is associated with a significant improvement in overall survival in ovarian cancer,” Cytokine, vol. 42, no. 1, pp. 77–84, 2008. View at Publisher · View at Google Scholar · View at PubMed
  41. E. L. Spaeth, J. L. Dembinski, A. K. Sasser et al., “Mesenchymal stem cell transition to tumor-associated fibroblasts contributes to fibrovascular network expansion and tumor progression,” PLoS ONE, vol. 4, no. 4, Article ID e4992, 2009. View at Publisher · View at Google Scholar · View at PubMed
  42. M. B. Nilsson, R. R. Langley, and I. J. Fidler, “Interleukin-6, secreted by human ovarian carcinoma cells, is a potent proangiogenic cytokine,” Cancer Research, vol. 65, no. 23, pp. 10794–10800, 2005. View at Publisher · View at Google Scholar · View at PubMed
  43. A. Rabinovich, L. Medina, B. Piura, S. Segal, and M. Huleihel, “Regulation of ovarian carcinoma SKOV-3 cell proliferation and secretion of MMPs by autocrine IL-6,” Anticancer Research A, vol. 27, no. 1, pp. 267–272, 2007. View at Google Scholar
  44. N. H. Obata, K. Tamakoshi, K. Shibata, F. Kikkawa, and Y. Tomoda, “Effects of Interleukin-6 on in vitro cell attachment, migration and invasion of human ovarian carcinoma,” Anticancer Research A, vol. 17, no. 1, pp. 337–342, 1997. View at Google Scholar
  45. Y. Wang, X. L. Niu, Y. Qu et al., “Autocrine production of interleukin-6 confers cisplatin and paclitaxel resistance in ovarian cancer cells,” Cancer Letters, vol. 295, no. 1, pp. 110–123, 2010. View at Publisher · View at Google Scholar · View at PubMed
  46. G. Scambia, U. Testa, P. Benedetti Panici et al., “Prognostic significance of interleukin 6 serum levels in patients with ovarian cancer,” British Journal of Cancer, vol. 71, no. 2, pp. 354–356, 1995. View at Google Scholar
  47. R. T. Penson, K. Kronish, Z. Duan et al., “Cytokines IL-1β, IL-2, IL-6, IL-8, MCP-1, GM-CSF and TNFα in patients with epithelial ovarian cancer and their relationship to treatment with paclitaxel,” International Journal of Gynecological Cancer, vol. 10, no. 1, pp. 33–41, 2000. View at Publisher · View at Google Scholar
  48. V. D'Hondt, Y. Humblet, T. Guillaume et al., “Thrombopoietic effects and toxicity of interleukin-6 in patients with ovarian cancer before and after chemotherapy: a multicentric placebo- controlled, randomized phase Ib study,” Blood, vol. 85, no. 9, pp. 2347–2353, 1995. View at Google Scholar
  49. T. Edgell, G. Martin-Roussety, G. Barker et al., “Phase II biomarker trial of a multimarker diagnostic for ovarian cancer,” Journal of Cancer Research and Clinical Oncology, vol. 136, no. 7, pp. 1079–1088, 2010. View at Publisher · View at Google Scholar · View at PubMed
  50. E. A. Jarboe, A. K. Folkins, R. Drapkin, T. A. Ince, E. S. Agoston, and C. P. Crum, “Tubal and ovarian pathways to pelvic epithelial cancer: a pathological perspective,” Histopathology, vol. 53, no. 2, pp. 127–138, 2008. View at Publisher · View at Google Scholar · View at PubMed
  51. N. Auersperg, S. L. Maines-Bandiera, H. G. Dyck, and P. A. Kruk, “Characterization of cultured human ovarian surface epithelial cells: phenotypic plasticity and premalignant changes,” Laboratory Investigation, vol. 71, no. 4, pp. 510–518, 1994. View at Google Scholar
  52. P. A. Kruk and N. Auersperg, “Human ovarian surface epithelial cells are capable of physically restructuring extracellular matrix,” American Journal of Obstetrics and Gynecology, vol. 167, no. 5, pp. 1437–1443, 1992. View at Google Scholar
  53. P. A. Kruk, V. J. Uitto, J. D. Firth, S. Dedhar, and N. Auersperg, “Reciprocal interactions between human ovarian surface epithelial cells and adjacent extracellular matrix,” Experimental Cell Research, vol. 215, no. 1, pp. 97–108, 1994. View at Publisher · View at Google Scholar · View at PubMed
  54. N. Auersperg, I. A. Maclaren, and P. A. Kruk, “Ovarian surface epithelium: autonomous production of connective tissue-type extracellular matrix,” Biology of Reproduction, vol. 44, no. 4, pp. 717–724, 1991. View at Google Scholar
  55. D. Vergara, B. Merlot, J. P. Lucot et al., “Epithelial-mesenchymal transition in ovarian cancer,” Cancer Letters, vol. 291, no. 1, pp. 59–66, 2010. View at Publisher · View at Google Scholar · View at PubMed
  56. B. Gondos, “Surface epithelium of the developing ovary. Possible correlation with ovarian neoplasia,” American Journal of Pathology, vol. 81, no. 2, pp. 303–312, 1975. View at Google Scholar
  57. W. Shan and J. Liu, “Inflammation: a hidden path to breaking the spell of ovarian cancer,” Cell Cycle, vol. 8, no. 19, pp. 3107–3111, 2009. View at Google Scholar
  58. R. B. Ness, J. A. Grisso, C. Cottreau et al., “Factors related to inflammation of the ovarian epithelium and risk of ovarian cancer,” Epidemiology, vol. 11, no. 2, pp. 111–117, 2000. View at Publisher · View at Google Scholar
  59. L. S. Angelo and R. Kurzrock, “Vascular endothelial growth factor and its relationship to inflammatory mediators,” Clinical Cancer Research, vol. 13, no. 10, pp. 2825–2830, 2007. View at Publisher · View at Google Scholar · View at PubMed
  60. N. Auersperg, J. Pan, B. D. Grove et al., “E-cadherin induces mesenchymal-to-epithelial transition in human ovarian surface epithelium,” Proceedings of the National Academy of Sciences of the United States of America, vol. 96, no. 11, pp. 6249–6254, 1999. View at Publisher · View at Google Scholar
  61. S. Elloul, O. Vaksman, H. T. Stavnes, C. G. Trope, B. Davidson, and R. Reich, “Mesenchymal-to-epithelial transition determinants as characteristics of ovarian carcinoma effusions,” Clinical and Experimental Metastasis, vol. 27, no. 3, pp. 161–172, 2010. View at Publisher · View at Google Scholar · View at PubMed
  62. J. P. Their, “Epithelial-mesenchymal transitions in tumor progression,” Nature Reviews Cancer, vol. 2, no. 6, pp. 442–454, 2002. View at Google Scholar
  63. K. Kitagawa, A. Murata, N. Matsuura et al., “Epithelial-mesenchymal transformation of a newly established cell line from ovarian adenosarcoma by transforming growth factor-β1,” International Journal of Cancer, vol. 66, no. 1, pp. 91–97, 1996. View at Google Scholar
  64. N. Ahmed, S. Maines-Bandiera, M. A. Quinn, W. G. Unger, S. Dedhar, and N. Auersperg, “Molecular pathways regulating EGF-induced epithelio-mesenchymal transition in human ovarian surface epithelium,” American Journal of Physiology, vol. 290, no. 6, pp. C1532–C1542, 2006. View at Publisher · View at Google Scholar · View at PubMed
  65. Y. L. Pon, H. Y. Zhou, A. N. Y. Cheung, H. Y. S. Ngan, and A. S. T. Wong, “p70 S6 kinase promotes epithelial to mesenchymal transition through snail induction in ovarian cancer cells,” Cancer Research, vol. 68, no. 16, pp. 6524–6532, 2008. View at Publisher · View at Google Scholar · View at PubMed
  66. L. Rosanò, F. Spinella, V. Di Castro et al., “Endothelin-1 promotes epithelial-to-mesenchymal transition in human ovarian cancer cells,” Cancer Research, vol. 65, no. 24, pp. 11649–11657, 2005. View at Publisher · View at Google Scholar · View at PubMed
  67. B. L. Thériault, T. G. Shepherd, M. L. Mujoomdar, and M. W. Nachtigal, “BMP4 induces EMT and Rho GTPase activation in human ovarian cancer cells,” Carcinogenesis, vol. 28, no. 6, pp. 1153–1162, 2007. View at Publisher · View at Google Scholar · View at PubMed
  68. M. Colomiere, A. C. Ward, C. Riley et al., “Cross talk of signals between EGFR and IL-6R through JAK2/STAT3 mediate epithelial-mesenchymal transition in ovarian carcinomas,” British Journal of Cancer, vol. 100, no. 1, pp. 134–144, 2009. View at Publisher · View at Google Scholar · View at PubMed
  69. H. Kajiyama, K. Shibata, M. Terauchi et al., “Chemoresistance to paclitaxel induces epithelial-mesenchymal transition and enhances metastatic potential for epithelial ovarian carcinoma cells,” International Journal of Oncology, vol. 31, no. 2, pp. 277–283, 2007. View at Google Scholar
  70. F. Collino, A. Revelli, M. Massobrio et al., “Epithelial-mesenchymal transition of ovarian tumor cells induces an angiogenic monocyte cell population,” Experimental Cell Research, vol. 315, no. 17, pp. 2982–2994, 2009. View at Publisher · View at Google Scholar · View at PubMed
  71. M. A. Merritt, A. C. Green, C. M. Nagle et al., “Talcum powder, chronic pelvic inflammation and NSAIDs in relation to risk of epithelial ovarian cancer,” International Journal of Cancer, vol. 122, no. 1, pp. 170–176, 2008. View at Publisher · View at Google Scholar · View at PubMed
  72. A. Tavani, S. Gallus, C. La Vecchia, E. Conti, M. Montella, and S. Franceschi, “Aspirin and ovarian cancer: an italian case-control study,” Annals of Oncology, vol. 11, no. 9, pp. 1171–1173, 2000. View at Publisher · View at Google Scholar
  73. T. Sueblinvong and M. E. Carney, “Current understanding of risk factors for ovarian cancer,” Current Treatment Options in Oncology, vol. 10, no. 1-2, pp. 67–81, 2009. View at Publisher · View at Google Scholar · View at PubMed
  74. M. A. McSorley, A. J. Alberg, D. S. Allen et al., “C-reactive protein concentrations and subsequent ovarian cancer risk,” Obstetrics and Gynecology, vol. 109, no. 4, pp. 933–941, 2007. View at Publisher · View at Google Scholar · View at PubMed
  75. R. B. Ness and F. Modugno, “Endometriosis as a model for inflammation-hormone interactions in ovarian and breast cancers,” European Journal of Cancer, vol. 42, no. 6, pp. 691–703, 2006. View at Publisher · View at Google Scholar · View at PubMed
  76. S. C. Mok, J. Kwong, W. R. Welch et al., “Etiology and pathogenesis of epithelial ovarian cancer,” Disease Markers, vol. 23, no. 5-6, pp. 367–376, 2007. View at Google Scholar
  77. M. Mandai, K. Yamaguchi, N. Matsumura, T. Baba, and I. Konishi, “Ovarian cancer in endometriosis: molecular biology, pathology, and clinical management,” International Journal of Clinical Oncology, vol. 14, no. 5, pp. 383–391, 2009. View at Publisher · View at Google Scholar · View at PubMed
  78. Y. Yamada, H. Shigetomi, A. Onogi et al., “New insights into pattern recognition receptors and their ligands in gynecologic pathologies,” Human Immunology, vol. 72, no. 3, pp. 213–218, 2011. View at Publisher · View at Google Scholar · View at PubMed
  79. R. B. Ness, “Endometriosis and ovarian cancer: thoughts on shared pathophysiology,” American Journal of Obstetrics and Gynecology, vol. 189, no. 1, pp. 280–294, 2003. View at Publisher · View at Google Scholar
  80. A. G. J. van der Zee, E. M. J. De Cuyper, P. C. Limburg et al., “Higher levels of interleukin-6 in cystic fluids from patients with malignant versus benign ovarian tumors correlate with decreased hemoglobin levels and increased platelet counts,” Cancer, vol. 75, no. 4, pp. 1004–1009, 1995. View at Google Scholar
  81. H. Tilg, C. A. Dinarello, and J. W. Mier, “IL-6 and APPs: anti-inflammatory and immunosuppressive mediators,” Immunology Today, vol. 18, no. 9, pp. 428–432, 1997. View at Publisher · View at Google Scholar
  82. N. Paland, I. Kamer, I. Kogan-Sakin, S. Madar, N. Goldfinger, and V. Rotter, “Differential influence of normal and cancer-associated fibroblasts on the growth of human epithelial cells in an in vitro cocultivation model of prostate cancer,” Molecular Cancer Research, vol. 7, no. 8, pp. 1212–1223, 2009. View at Publisher · View at Google Scholar · View at PubMed
  83. W. C. Gorospe and B. L. Spangelo, “Interleukin-6 production by rat granulosa cells in vitro: effects of cytokines, follicle-stimulating hormone, and cyclic 3',5'-adenosine monophosphate,” Biology of Reproduction, vol. 48, no. 3, pp. 538–543, 1993. View at Publisher · View at Google Scholar
  84. Y. J. Lidor, F. J. Xu, O. Martinez-Maza et al., “Constitutive production of macrophage colony-stimulating factor and interleukin-6 by human ovarian surface epithelial cells,” Experimental Cell Research, vol. 207, no. 2, pp. 332–339, 1993. View at Publisher · View at Google Scholar · View at PubMed
  85. J. M. Waton, J. L. Sensintaffar, J. S. Berek, and O. Martinez-Maza, “Constitutive production of interleukin 6 by ovarian cancer cell lines and by primary ovrian tumor cultures,” Cancer Research, vol. 50, no. 21, pp. 6959–6965, 1990. View at Google Scholar
  86. J. G. W. Asschert, E. Vellenga, H. Hollema, A. G. J. Van Der Zee, and E. G. E. De Vries, “Expression of macrophage colony-stimulating factor (M-CSF), interleukin-6 (IL-6), interleukin-1β (IL-1β), interleukin-11 (IL-11) and tumour necrosis factor-α (TNF-α) in p53-characterised human ovarian carcinomas,” European Journal of Cancer, vol. 33, no. 13, pp. 2246–2251, 1997. View at Google Scholar
  87. A. Erroi, M. Sironi, F. Chiaffarino, C. Zhen-Guo, M. Mengozzi, and A. Mantovani, “IL-1 and IL-6 release by tumor-associated macrophages from human ovarian carcinoma,” International Journal of Cancer, vol. 44, no. 5, pp. 795–801, 1989. View at Publisher · View at Google Scholar
  88. J. S. Berek, C. Chung, K. Kaldi, J. M. Watson, R. M. Knox, and O. Martinez-Maza, “Serum interleukin-6 levels correlate with disease status in patients with epithelial ovarian cancer,” American Journal of Obstetrics and Gynecology, vol. 164, no. 4, pp. 1038–1043, 1991. View at Google Scholar
  89. G. Gastl, M. Plante, C. L. Finstad et al., “High IL-6 levels in ascitic fluid correlate with reactive thrombocytosis in patients with epithelial ovarian cancer,” British Journal of Haematology, vol. 83, no. 3, pp. 433–441, 1993. View at Google Scholar
  90. N. Auersperg, A. S. T. Wong, K. C. Choi, S. K. Kang, and P. C. K. Leung, “Ovarian surface epithelium: biology, endocrinology, and pathology,” Endocrine Reviews, vol. 22, no. 2, pp. 255–288, 2001. View at Publisher · View at Google Scholar
  91. F. A. Offner, P. Obrist, S. Stadlmann et al., “IL-6 secretion by human peritoneal mesothelial and ovarian cancer cells,” Cytokine, vol. 7, no. 6, pp. 542–547, 1995. View at Publisher · View at Google Scholar
  92. C. A. Dinarello, “Biologic basis for interleukin-1 in disease,” Blood, vol. 87, no. 6, pp. 2095–2147, 1996. View at Google Scholar
  93. E. Stylianou and J. Saklatvala, “Interleukin-1,” International Journal of Biochemistry and Cell Biology, vol. 30, no. 10, pp. 1075–1079, 1998. View at Publisher · View at Google Scholar
  94. H. J. Ziltener, S. Maines-Bandiera, J. W. Schrader, and N. Auersperg, “Secretion of bioactive interleukin-1, interleukin-6, and colony- stimulating factors by human ovarian surface epithelium,” Biology of Reproduction, vol. 49, no. 3, pp. 635–641, 1993. View at Google Scholar
  95. A. M. Lewis, S. Varghese, H. Xu, and H. R. Alexander, “Interleukin-1 and cancer progression: the emerging role of interleukin-1 receptor antagonist as a novel therapeutic agent in cancer treatment,” Journal of Translational Medicine, vol. 4, article 48, 2006. View at Publisher · View at Google Scholar · View at PubMed
  96. I. Cohen, P. Rider, Y. Carmi et al., “Differential release of chromatin-bound IL-1α discriminates between necrotic and apoptotic cell death by the ability to induce sterile inflammation,” Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 6, pp. 2574–2579, 2010. View at Publisher · View at Google Scholar · View at PubMed
  97. C. A. Dinarello, “The paradox of pro-inflammatory cytokines in cancer,” Cancer and Metastasis Reviews, vol. 25, no. 3, pp. 307–313, 2006. View at Publisher · View at Google Scholar · View at PubMed
  98. W. P. Arend, G. Palmer, and C. Gabay, “IL-1, IL-18, and IL-33 families of cytokines,” Immunological Reviews, vol. 223, no. 1, pp. 20–38, 2008. View at Publisher · View at Google Scholar · View at PubMed
  99. R. A. Burger, E. A. Grosen, G. R. Ioli et al., “Host-tumor interaction in ovarian cancer: spontaneous release of tumor necrosis factor and interleukin-1 inhibitors by purified cell populations from human ovarian carcinoma in vitro,” Gynecologic Oncology, vol. 55, no. 2, pp. 294–303, 1994. View at Publisher · View at Google Scholar · View at PubMed
  100. P. Y. K. Yong, C. Harlow, K. J. Thong, and S. G. Hillier, “Regulation of 11β-hydroxysteroid dehydrogenase type 1 gene expression in human ovarian surface epithelial cells by interleukin-1,” Human Reproduction, vol. 17, no. 9, pp. 2300–2306, 2002. View at Google Scholar
  101. M. T. Rae, D. Niven, A. Ross et al., “Steroid signalling in human ovarian surface epithelial cells: the response to interleukin-1α determined by microarray analysis,” Journal of Endocrinology, vol. 183, no. 1, pp. 19–28, 2004. View at Publisher · View at Google Scholar · View at PubMed
  102. S. G. Hillier and M. Tetsuka, “An anti-inflammatory role for glucocorticoids in the ovaries?” Journal of Reproductive Immunology, vol. 39, no. 1-2, pp. 21–27, 1998. View at Publisher · View at Google Scholar
  103. S. Temkin, V. L. Nacharaju, M. Hellman, Y. C. Lee, and O. Abulafia, “Type 2 11β-hydroxysteroid dehydrogenase activity in human ovarian cancer,” Steroids, vol. 71, no. 11-12, pp. 1019–1023, 2006. View at Publisher · View at Google Scholar · View at PubMed
  104. O. Gubbay, W. Guo, M. T. Rae, D. Niven, S. P. Langdon, and S. G. Hillier, “Inflammation-associated gene expression is altered between normal human ovarian surface epithelial cells and cell lines derived from ovarian adenocarcinomas,” British Journal of Cancer, vol. 92, no. 10, pp. 1927–1933, 2005. View at Publisher · View at Google Scholar · View at PubMed
  105. E. H. Rabbitt, N. J. L. Gittoes, P. M. Stewart, and M. Hewison, “11β-hydroxysteroid dehydrogenases, cell proliferation and malignancy,” Journal of Steroid Biochemistry and Molecular Biology, vol. 85, no. 2–5, pp. 415–421, 2003. View at Publisher · View at Google Scholar
  106. C. F. Verschraegen, A. P. Kudelka, W. Termrungruanglert et al., “Effects of interleukin-la on ovarian carcinoma in patients with recurrent disease,” European Journal of Cancer Part A, vol. 32, no. 9, pp. 1609–1611, 1996. View at Google Scholar
  107. J. Crown, A. Jakubowski, N. Kemeny et al., “A phase I trial of recombinant human interleukin-1β alone and in combination with myelosuppressive doses of 5-fluorouracil in patients with gastrointestinal cancer,” Blood, vol. 78, no. 6, pp. 1420–1427, 1991. View at Google Scholar · View at Scopus
  108. I. Mitroulis, P. Skendros, and K. Ritis, “Targeting IL-1β in disease; the expanding role of NLRP3 inflammasome,” European Journal of Internal Medicine, vol. 21, no. 3, pp. 157–163, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus